AMARIN CORP PLC -ADR (AMRN) Stock Price & Overview
NASDAQ:AMRN • US0231114044
Current stock price
The current stock price of AMRN is 14.72 USD. Today AMRN is down by -3.16%. In the past month the price decreased by -1.47%. In the past year, price increased by 61.58%.
AMRN Key Statistics
- Market Cap
- 306.069M
- P/E
- N/A
- Fwd P/E
- 37.98
- EPS (TTM)
- -0.01
- Dividend Yield
- N/A
AMRN Stock Performance
AMRN Stock Chart
AMRN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AMRN. When comparing the yearly performance of all stocks, AMRN is one of the better performing stocks in the market, outperforming 82.27% of all stocks.
AMRN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AMRN. AMRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AMRN Earnings
On February 25, 2026 AMRN reported an EPS of 0.01 and a revenue of 49.22M. The company missed EPS expectations and missed revenue expectations (-4.67% surprise).
AMRN Forecast & Estimates
7 analysts have analysed AMRN and the average price target is 12.24 USD. This implies a price decrease of -16.85% is expected in the next year compared to the current price of 14.72.
For the next year, analysts expect an EPS growth of 3976% and a revenue growth -18.92% for AMRN
AMRN Groups
Sector & Classification
AMRN Financial Highlights
Over the last trailing twelve months AMRN reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS increased by 99.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.78% | ||
| ROE | -8.45% | ||
| Debt/Equity | 0 |
AMRN Ownership
AMRN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.09 | 369.653B | ||
| AMGN | AMGEN INC | 15.3 | 188.346B | ||
| GILD | GILEAD SCIENCES INC | 15.67 | 171.971B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.37 | 110.812B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.91 | 78.867B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.9 | 42.456B | ||
| INSM | INSMED INC | N/A | 30.821B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.581B | ||
| NTRA | NATERA INC | N/A | 27.795B | ||
| BIIB | BIOGEN INC | 10.92 | 25.833B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.86 | 25.444B | ||
| MRNA | MODERNA INC | N/A | 21.686B | ||
| INCY | INCYTE CORP | 12.32 | 18.97B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AMRN
Company Profile
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Company Info
IPO: 1993-04-01
AMARIN CORP PLC -ADR
WeWork One Central Plaza Dame Street, Dublin 2
DUBLIN Dublin 2 IE
CEO: John F. Thero
Employees: 80
Phone: 35316699020
AMARIN CORP PLC -ADR / AMRN FAQ
What does AMRN do?
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
What is the current price of AMRN stock?
The current stock price of AMRN is 14.72 USD. The price decreased by -3.16% in the last trading session.
Does AMRN stock pay dividends?
AMRN does not pay a dividend.
What is the ChartMill rating of AMARIN CORP PLC -ADR stock?
AMRN has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for AMARIN CORP PLC -ADR?
The Revenue of AMARIN CORP PLC -ADR (AMRN) is expected to decline by -18.92% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of AMARIN CORP PLC -ADR (AMRN) stock?
The outstanding short interest for AMARIN CORP PLC -ADR (AMRN) is 44.29% of its float.